ArticleScientific reports2022
Leukocyte glucose index as a novel biomarker for COVID-19 severity.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Leukocyte glucose index discriminates metabolic dysfunction-associated steatotic liver disease from type 2 diabetes: a finding independent of oral antidiabetic therapy.Gastroenterology and hepatology from bed to bench · 2026Article
- The leukocyte glucose index: a novel inflammatory-glucose biomarker for prevalent diabetic retinopathy and its supplementary predictive capacity in individuals with type 2 diabetes mellitus.Frontiers in endocrinology · 2026Article
- The predictive value of the leuko-glycemic index in spontaneous intracerebral hemorrhage patients undergoing neurosurgical operation: a retrospective cohort study.Frontiers in neurology · 2026Article
- Association of leuko-glycemic index with mortality in critically ill stroke patients: analysis from the MIMIC-IV database and an institutional cohort.Frontiers in medicine · 2026Article
- The role of the leukocyte glucose index in predicting clinical outcomes in acute methanol toxicity.Toxicology reports · 2025Article
- Elevated Leukocyte Glucose Index (LGI) Is Associated with Diabetic Ketoacidosis (DKA) Severity and Presence of Microvascular Complications.Medicina (Kaunas, Lithuania) · 2025Observational
- Leukoglycemic Index and Its Prognostic Implications in Diabetic and Nondiabetic Patients with Acute Pulmonary Embolism.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Association between leuko-glycemic index and mortality in critically ill patients with non-traumatic subarachnoid hemorrhage: analysis of the MIMIC-IV database.Frontiers in neurology · 2025Article
- The Model for End-Stage Liver Disease (MELD) Score Predicting Mortality Due to SARS-CoV-2 in Mexican Patients.Journal of clinical medicine · 2024Article
- Association between lipid profile and clinical outcomes in COVID-19 patients.Scientific reports · 2024Article
- Acute Kidney Injury in the Context of COVID-19: An Analysis in Hospitalized Mexican Patients.Infectious disease reports · 2024Article
- Elevated Leukocyte Glucose Index Is Associated with Long-Term Arteriovenous Fistula Failure in Dialysis Patients.Journal of clinical medicine · 2024Article
- The Role of Aspartate Aminotransferase-to-Lymphocyte Ratio Index (ALRI) in Predicting Mortality in SARS-CoV-2 Infection.Microorganisms · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severity of coronavirus disease 2019 (COVID-19) quickly progresses with unfavorable outcomes due to the host immune response and metabolism alteration. Hence, we hypothesized that leukocyte glucose index (LGI) is a biomarker for severe COVID-19. This study involved 109 patients and the usefulness of LGI was evaluated and compared with other risk factors to predict COVID 19 severity. LGI was identified as an independent risk factor (odds ratio [OR] = 1.727, 95% confidence interval [CI]: 1.026-3.048, P = 0.041), with an area under the curve (AUC) of 0.749 (95% CI: 0.642-0.857, P < 0.0001). Interestingly, LGI was a potential risk factor (OR = 2.694, 95% CI: 1.575-5.283, P
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.